Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH)

GE Portuguese Journal of Gastroenterology

Volumn 23, Issue 3, 2016, Pages 132-141

  Cortez Pinto, Helena ^a,b   Borralho, Paula ^b   Machado, Jorge ^c   Lopes, Maria T ^d   Gato, Inês V ^c   Santos, António M ^d   Guerreiro, António S ^d  

^a Centro Hospitalar Lisboa Norte   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^d NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

Mice; Microbiota; Non alcoholic Fatty Liver Disease; Prebiotics; Probiotics

Indexed keywords

EID: 85006220526     PISSN: 23414545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpge.2016.01.004     Document Type: Article

References (45)

1. Lonardo A., Bellentani S., Argo C.K., Ballestri S., Byrne C.D., Caldwell S.H., et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015, 47:997-1006.
2. Machado M.V., Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol 2014, 20:12956-12980.
3. Quigley E.M., Monsour H.P. The gut microbiota and nonalcoholic fatty liver disease. Semin Liver Dis 2015, 35:262-269.
4. Machado M.V., Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012, 11:440-449.
5. Le Roy T., Llopis M., Lepage P., Bruneau A., Rabot S., Bevilacqua C., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013, 62:1787-1794.
6. Mouzaki M., Comelli E.M., Arendt B.M., Bonengel J., Fung S.K., Fischer S.E., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58:120-127.
7. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
8. Boursier J., Mueller O., Barret M., Machado M., Fizanne L., Araujo-Perez F., et al. The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2015.
9. Csak T., Velayudham A., Hritz I., Petrasek J., Levin I., Lippai D., et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 2011, 300:G433-G441.
10. Miura K., Seki E., Ohnishi H., Brenner D.A. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010, 2010:362847.
11. Soares J.B., Pimentel-Nunes P., Roncon-Albuquerque R., Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 2010, 4:659-672.
12. Frasinariu O.E., Ceccarelli S., Alisi A., Moraru E., Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 2013, 45:543-551.
13. Portela-Cidade J., Borges-Canha M., Leite-Moreira A., Pimentel-Nunes P. Systematic review of the relation between intestinal microbiota and toll-like receptors in the metabolic syndrome: what do we know so far?. GE-Port J Gastroenterol 2015, 22:240-258.
14. Martens E.C., Lowe E.C., Chiang H., Pudlo N.A., Wu M., McNulty N.P., et al. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. PLoS Biol 2011, 9:e1001221.
15. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
16. Suarez-Zamorano N., Fabbiano S., Chevalier C., Stojanovic O., Colin D.J., Stevanovic A., et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat Med 2015, 21:1497-1501.
17. Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101:15718-15723.
18. Raubenheimer P.J., Nyirenda M.J., Walker B.R. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes 2006, 55:2015-2020.
19. Malkusch W., Rehn B., Bruch J. Advantages of Sirius Red staining for quantitative morphometric collagen measurements in lungs. Exp Lung Res 1995, 21:67-77.
20. Moter A., Gobel U.B. Fluorescence in situ hybridization (FISH) for direct visualization of microorganisms. J Microbiol Methods 2000, 41:85-112.
21. Amann R., Fuchs B.M., Behrens S. The identification of microorganisms by fluorescence in situ hybridisation. Curr Opin Biotechnol 2001, 12:231-236.
22. Ferolla S.M., Armiliato G.N., Couto C.A., Ferrari T.C. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients 2014, 6:5583-5599.
23. Miele L., Valenza V., La Torre G., Montalto M., Cammarota G., Ricci R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
24. Farhadi A., Gundlapalli S., Shaikh M., Frantzides C., Harrell L., Kwasny M.M., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28:1026-1033.
25. Harte A.L., da Silva N.F., Creely S.J., McGee K.C., Billyard T., Youssef-Elabd E.M., et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010, 7:15.
26. Ruiz A.G., Casafont F., Crespo J., Cayon A., Mayorga M., Estebanez A., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007, 17:1374-1380.
27. Pandey K.R., Naik S.R., Vakil B.V. Probiotics, prebiotics and synbiotics - a review. J Food Sci Technol 2015, 52:7577-7587.
28. Spindler-Vesel A., Bengmark S., Vovk I., Cerovic O., Kompan L. Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enteral Nutr 2007, 31:119-126.
29. Knight D.J., Gardiner D., Banks A., Snape S.E., Weston V.C., Bengmark S., et al. Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial. Intensive Care Med 2009, 35:854-861.
30. de La Serre C.B., Ellis C.L., Lee J., Hartman A.L., Rutledge J.C., Raybould H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010, 299:G440-G448.
31. Li D.Y., Yang M., Edwards S., Ye S.Q., Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr 2013.
32. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102:11070-11075.
33. Carr F.J., Chill D., Maida N. The lactic acid bacteria: a literature survey. Crit Rev Microbiol 2002, 28:281-370.
34. Zhu L., Baker S.S., Gill C., Liu W., Alkhouri R., Baker R.D., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.
35. Nair S., Cope K., Risby T.H., Diehl A.M. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:1200-1204.
36. Cope K., Risby T., Diehl A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119:1340-1347.
37. Turroni F., Marchesi J.R., Foroni E., Gueimonde M., Shanahan F., Margolles A., et al. Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME J 2009, 3:745-751.
38. Hotamisligil G.S. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes (Lond) 2008, 32(Suppl. 7):S52-S54.
39. Shoelson S.E., Goldfine A.B. Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat Med 2009, 15:373-374.
40. Stenman L.K., Holma R., Korpela R. High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. World J Gastroenterol 2012, 18:923-929.
41. Imajo K., Fujita K., Yoneda M., Nozaki Y., Ogawa Y., Shinohara Y., et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012, 16:44-54.
42. Feng C., Stamatos N.M., Dragan A.I., Medvedev A., Whitford M., Zhang L., et al. Sialyl residues modulate LPS-mediated signaling through the Toll-like receptor 4 complex. PLoS ONE 2012, 7:e32359.
43. Vespasiani-Gentilucci U., Carotti S., Perrone G., Mazzarelli C., Galati G., Onetti-Muda A., et al. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int 2015, 35:569-581.
44. Sepideh A., Karim P., Hossein A., Leila R., Hamdollah M., Mohammad E.G., et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr 2015, 1-6.
45. Iacono A., Raso G.M., Canani R.B., Calignano A., Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011, 22:699-711.